Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19
Nigel Stallard(University of Reading), Thomas Jaki(MRC Biostatistics Unit), Martin Posch(Medical University of Vienna), S. Faye Williamson(Lancaster University), Johannes Krisam(University Hospital Heidelberg), James Wason(MRC Biostatistics Unit), Gernot Wassmer(University of Cologne), Werner Brannath(University of Bremen), Lisa V. Hampson(Lancaster University), Tim Friede(Universitätsmedizin Göttingen), Pavel Mozgunov(University of Cambridge), Sarah Zohar(Inserm), John Whitehead(Lancaster City Council), Peter Kimani(University of Warwick), Franz Koenig(Medical University of Vienna), Norbert Benda(Federal Institute for Drugs and Medical Devices)
Cited by 7
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study
|PLoS Medicine|2019|1.1k
Adaptive designs in clinical trials: why use them, and how to run and report them
|BMC Medicine|2018|826
A general parametric approach to the meta‐analysis of randomized clinical trials
|Statistics in Medicine|1991|765